Clinical Trial Update: A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Valneva’s chikungunya vaccine VLA1553 in healthy children has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus Infection

Drugs mentioned

• VLA1553

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Chikungunya Virus Infection | Phase 3 | Status: WITHDRAWN